Pfizer Inc. (PFE)

NYQ – Real vaqt narxi. Valyuta: USD

26.31

-0.31 (-1.16%)

Yopilishda: Aug 12, 2026, 3:59 PM EDT

26.38

+0.07 (0.25%)

Bozordan keyin: Aug 12, 2026, 5:18 PM EDT

12.08.2026

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.

12.08.2026

The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More

Investors love S&P 500 dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.

11.08.2026

Pfizer's Pipeline Could Change Everything

Pfizer is recovering from post-COVID and LOE-driven declines, with recent earnings beats and an attractive valuation supporting upside potential. PFE's Q2 2026 results showed 1% operational revenue growth and a 12% EPS beat, driven by solid non-COVID sales and a robust growth portfolio. Cost Realignment Program expansions are set to deliver $7.2B in net savings by 2026 and another $2.5B through 2029, enhancing future earnings.

11.08.2026

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Pfizer still relies somewhat heavily on Eliquis, a medicine that will lose patent exclusivity relatively soon. The company is working on several products that could help it overcome this challenge.

11.08.2026

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

AbbVie has solid financials, tons of free cash flow, and it has tripled its dividend in the past decade. Pfizer's massive 6.4% yield may not be as risky as investors think, and the company has been investing in its future growth.

11.08.2026

Stop Chasing Yield: 2 Dividend Stocks I Want Now

Carlisle Companies offers a 1.3% yield, 50 years of dividend growth, and robust buybacks, supported by a low payout ratio and Vision 2030 targets. CSL's business is resilient due to commercial remodeling demand, with management targeting $40 EPS by 2030 and a potential doubling of the stock in 5–7 years. Pfizer yields 6.4% but faces near-term EPS declines. Dividend growth is paused until at least 2028 as the company rebuilds its drug pipeline.

10.08.2026

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Impairment charges crippled Pfizer's recent earnings. The company's free cash flow, however, remains fairly strong.

Videolar

No Data

There is no data to display

Press-relizlar

04.08.2026

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter, delivering on our financial commitments and adva.

Pfizer Inc. (PFE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pfizer Inc. (PFE)

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More

Pfizer's Pipeline Could Change Everything

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

Stop Chasing Yield: 2 Dividend Stocks I Want Now

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Videolar

No Data

Press-relizlar

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More

Pfizer's Pipeline Could Change Everything

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

Stop Chasing Yield: 2 Dividend Stocks I Want Now

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Videolar

No Data

Press-relizlar

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Search stocks

Pfizer Inc. (PFE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pfizer Inc. (PFE)

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More

Pfizer's Pipeline Could Change Everything

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

Stop Chasing Yield: 2 Dividend Stocks I Want Now

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Videolar

No Data

Press-relizlar

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More

Pfizer's Pipeline Could Change Everything

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

Stop Chasing Yield: 2 Dividend Stocks I Want Now

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Videolar

No Data

Press-relizlar

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance